GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » Short Percentage of Float

Acarix AB (OSTO:ACARIX) Short Percentage of Float


View and export this data going back to 2016. Start your Free Trial

What is Acarix AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Acarix AB's Short Percentage of Float

For the Medical Devices subindustry, Acarix AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acarix AB's Short Percentage of Float Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Acarix AB's Short Percentage of Float falls into.


Acarix AB (OSTO:ACARIX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » Short Percentage of Float
Comparable Companies
OSTO:ARCOMA OSTO:SCIB OSTO:ICO XSAT:PHI XSAT:VSD B NGM:MCLR OSTO:SDOS XSAT:REDS XSAT:CSMED OSTO:NEOLA ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
ACIXF:USA 7AC:Germany
Address
World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19
Website
https://www.acarix.com
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96% certainty.

Acarix AB (OSTO:ACARIX) Headlines

No Headlines